JMP Securities analyst Jason Butler reiterated a Buy rating on Argenx Se (ARGX – Research Report) today and set a price target of $443.00. The company’s shares opened today at $377.58.
Butler covers the Healthcare sector, focusing on stocks such as Esperion, Aquestive Therapeutics, and Cytokinetics. According to TipRanks, Butler has an average return of -6.1% and a 42.37% success rate on recommended stocks.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $463.90, which is a 22.86% upside from current levels. In a report released on January 25, Cowen & Co. also maintained a Buy rating on the stock with a $458.00 price target.
See the top stocks recommended by analysts >>
Based on Argenx Se’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $137.98 million and a GAAP net loss of $235.04 million. In comparison, last year the company earned a revenue of $857 thousand and had a GAAP net loss of $233.61 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX:
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- Argenx price target raised to $458 from $441 at Cowen
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- Argenx reports preliminary Q4 Vyvgart revenue $175M
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
